Want to see ETON full AI Analyst Report?
ETON Stock Chart & Stats
$63.05
$1.05(2.47%)
At close: 4:00 PM EDT
$63.05
$1.05(2.47%)
Day’s Range― - ―
52-Week Range$14.27 - $66.37
Previous CloseN/A
Volume7.82K
Average Volume (3M)573.46K
Market Cap
$1.63B
Enterprise Value$1.19K
Total Cash (Recent Filing)$26.84M
Total Debt (Recent Filing)$28.99M
Price to Earnings (P/E)119.4
Beta0.56
Next Earnings
Nov 05, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.47
Shares Outstanding28,583,136
10 Day Avg. Volume344,333
30 Day Avg. Volume573,459
Financial Highlights & Ratios
PEG Ratio-7.46
Price to Book (P/B)17.40
Price to Sales (P/S)5.69
P/FCF Ratio44.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$61.50Price Target Upside-2.46% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.05
Revenue Forecast (FY)$128.20M
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability InflectionThe move to meaningful revenue growth and positive margins indicates Eton’s commercial portfolio is gaining scale. If sustained, the improved gross profit base can fund product investment internally, support operating leverage, and establish a stronger earnings foundation over the next several quarters.
Raised Growth And Margin OutlookHigher full-year revenue and EBITDA guidance, following 99% Q2 revenue growth and a 43% adjusted EBITDA margin, signals broad commercial momentum and improving economics. This outlook supports durable expansion if launches, reimbursement access, and portfolio execution remain on schedule.
Deleveraging And Cash GenerationSubstantial debt reduction alongside positive operating and free cash flow improves financial flexibility. A less levered balance sheet gives Eton more capacity to repay facilities, absorb development spending, and pursue product opportunities without relying as heavily on external capital.
Bears Say
Limited Profitability Track RecordAlthough current results are profitable, the recent history of near-breakeven or loss-making performance means sustained earnings power has not yet been demonstrated across multiple periods. A short profitability record makes future margins more dependent on continued portfolio growth and execution.
Cash Demands From Development InvestmentsThe cash balance must support planned licensing, clinical, and regulatory investments while management also accelerates debt repayment. These commitments could limit near-term financial flexibility and create pressure on cash generation if development timelines extend or commercial growth moderates.
Lower-margin IMPAVIDO EconomicsA large partner profit share means IMPAVIDO should contribute less margin than Eton’s higher-margin in-house products, even if sales expand. This can dilute consolidated profitability and makes the value of the launch more dependent on achieving sufficient volume to offset the economics.
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals Inc’s price range in the past 12 months?
Eton Pharmaceuticals Inc lowest stock price was $14.27 and its highest was $66.37 in the past 12 months.
What is Eton Pharmaceuticals Inc’s market cap?
Eton Pharmaceuticals Inc’s market cap is $1.63B.
When is Eton Pharmaceuticals Inc’s upcoming earnings report date?
Eton Pharmaceuticals Inc’s upcoming earnings report date is Nov 05, 2026 which is in 46 days.
How were Eton Pharmaceuticals Inc’s earnings last quarter?
Eton Pharmaceuticals Inc released its earnings results on Aug 13, 2026. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.16.
Is Eton Pharmaceuticals Inc overvalued?
According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Overvalued.
Does Eton Pharmaceuticals Inc pay dividends?
Eton Pharmaceuticals Inc does not currently pay dividends.
What is Eton Pharmaceuticals Inc’s EPS estimate?
Eton Pharmaceuticals Inc’s EPS estimate is 0.31.
How many shares outstanding does Eton Pharmaceuticals Inc have?
Eton Pharmaceuticals Inc has 28,583,136 shares outstanding.
What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?
Eton Pharmaceuticals Inc reported an EPS of $0.35 in its last earnings report, beating expectations of $0.19. Following the earnings report the stock price went up 44.265%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ETON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eton Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.50 (-2.46% Downside)
$61.50 (-2.46% Downside)
Blogger Sentiment
Neutral
ETON Sentiment 56%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 140.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $18.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 16.4%
Last 30 Days ▲ 16.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, broad-based commercial momentum (record revenue +99% YoY), significant margin expansion (adjusted EBITDA to $16.2M; 43% margin), strategic portfolio expansion (HEMANGEOL relaunch, ASN-001 and IMPAVIDO additions), and raised full-year guidance, demonstrating positive operational execution and scalable economics. Key risks include modest cash after recent transactions, near-term R&D and acquisition-related expenses (including a $3M ASN-001 upfront and ~$4M bioavailability study), slightly lower adjusted gross margin driven by non-U.S. Increlex sales, and execution/timing risk around several pending regulatory and clinical milestones. Overall, positives materially outweigh the manageable lowlights given the magnitude of revenue and profitability improvements and upgraded guidance.View all ETON earnings summariesETON Stock 12 Month Forecast
Average Price Target
$61.50
▼(-2.46% Downside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Cumberland Pharmaceuticals
―
Ownership Overview
14.96% Insiders
6.61% Mutual Funds
35.34% Other Institutional Investors
32.14% Public Companies and
Individual Investors